The new indication application is primarily based on the results of the pivotal Phase II clinical study MIZAR-003. MIZAR-003 ...

Sac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial ...

The Company will initiate its planned clinical study of BIO 300 Injectable Suspension, subject to Institutional Review Board ...

AM ET SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value ...

An accomplished biotechnology executive, Ms. Pussinen brings more than 30 years of global leadership experience spanning ...

Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: ...

IAM1363, now in a Phase 1/1b study, was designed using Iambic’s molecular superintelligence platform and brought to clinical ...

MustGrow recently announced the receipt of its first development milestone payment Bayer, part of their License and ...

Pluri Inc. (Nasdaq and TASE: PLUR) (“Pluri”) and ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO”) today announced a definitive ...

After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, ...

October 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and ...

While biopharma financing exit activity has remained strong through the third quarter, public-market performance for the same ...